Results 61 to 70 of about 272,512 (195)

Unfavorable Outcome of Neuroblastoma in Patients With 2p Gain

Frontiers in Oncology, 2019
Background: Amplification of the MYCN oncogene is the most unfavorable genetic factor in neuroblastoma patients. However, knowledge about the clinical impact of low-level multiplication of MYCN is still insufficient.
Katarzyna Szewczyk, Aleksandra Wieczorek, Aleksandra Wieczorek, Wojciech Młynarski, Szymon Janczar, Mariola Woszczyk, Zuzanna Gamrot, Radosław Chaber, Mariusz Wysocki, Monika Pogorzała, Mirosław Bik-Multanowski, Walentyna Balwierz, Walentyna Balwierz   +12 more
doaj   +1 more source

The FGF/FGFR System in the Biology and Therapeutic Landscape of Pediatric CNS Tumors

Medicinal Research Reviews, EarlyView.
ABSTRACT Central nervous system (CNS) tumors are the most common solid malignancies in children, comprising a highly heterogeneous group of neoplasms defined by distinct molecular alterations and clinical behaviors. Advances in molecular genetics have underscored the relevance of specific signaling pathways in driving pediatric tumorigenesis, among ...
Serena Filiberti, Camilla Tavani, Elena Somenza, Nicolas Tassone, Antonio d'Amati, Marta Turati, Roberto Ronca   +6 more
wiley   +1 more source

Application of the FISH method and high-density SNP arrays to assess genetic changes in neuroblastoma—research by one institute

Acta Biochimica Polonica
Neuroblastoma is the most common extracranial solid tumor in children. Amplification of the MYCN gene has been observed in approximately 20%–30% of tumors.
Dorota Winnicka, Paulina Skowera, Magdalena Stelmach, Borys Styka, Monika Lejman   +4 more
doaj   +1 more source

Interventional oncology in children: Where are we now?

Journal of Medical Imaging and Radiation Oncology, EarlyView.
Abstract Paediatric Interventional Oncology (IO) lags behind adult IO due to a scarcity of specific outcome data. The suboptimal way to evolve this field is relying heavily on adult experiences. The distinct tumour types prevalent in children, such as extracranial germ cell tumours, sarcomas, and neuroblastoma, differ strongly from those found in ...
Premal Amrishkumar Patel, Fernando Gómez Muñoz   +1 more
wiley   +1 more source

Evaluation of MYCN immunohistochemistry as a cost-effective surrogate for MYCN genetic testing

, 2022
Background: Background: MYCN amplified neuroblastomas are associated with poor prognosis. Fluorescence in-situ Hybridization (FISH) is the recommended technique to identify MYCN amplification.
Aditya Jadav, Charvy Rana, Aanchal Kakkar, V.K. Iyer, Iyer, V.K., Bakhshi, Sameer, Rana, Charvy, Burra Shivani Srivastava, Antony, Abin, Srivastava, Burra Shivani, Sandeep Agarwala, Sameer Bakhshi, Jadav, Aditya, Aditya Gupta, Kakkar, Aanchal, Agarwala, Sandeep, Abin Antony, Gupta, Aditya   +17 more
core   +1 more source

Neuroblastomas in Eastern China: a retrospective series study of 275 cases in a regional center [PDF]

PeerJ, 2018
Purpose Most studies on neuroblastoma (NB) have been conducted in Western countries or Japan. The objective of our study was to analyze clinical and pathological features, MYCN status, surgical methods, and prognosis in Chinese NB patients.
Yangyang Ma, Jicui Zheng, Jiayan Feng, Lian Chen, Kuiran Dong, Xianmin Xiao   +5 more
doaj   +2 more sources

AOSNP‐ADAPTR resource level‐based recommendations on practical diagnostic strategies for ependymomas

Brain Pathology, EarlyView.
Adapting Diagnostic Approaches for Practical Taxonomy in Resource‐Restrained Regions (ADAPTR) recommendations for ependymomas in resource‐restrained settings (RL = resource level; created in BioRender). Abstract Ependymomas are uncommon primary tumors of the central nervous system (CNS) that affect both children and adults.
Laveniya Satgunaseelan, Michael E. Buckland, Geeta Chacko, Kenta Masui, Junji Shibahara, Vani Santosh, Maysa Al‐Hussaini, Sung‐Hye Park, Tarik Tihan, Ho‐Keung Ng, Pieter Wesseling, David N. Louis, Chitra Sarkar, Takashi Komori   +13 more
wiley   +1 more source

MRI-based radiomic signature for MYCN amplification prediction of pediatric abdominal neuroblastoma [PDF]

Sensors & Diagnostics
MYCN gene amplification critically drives neuroblastoma aggressiveness and poor outcomes, necessitating precise preoperative identification to guide risk-adapted therapies.
Xuan Jia, Junjie Wen, Jiawei Liang, Xiaohui Ma, Wenqi Wang, Jinhu Wang, Yi Zhang   +6 more
doaj   +1 more source

Interlaboratory performance testing on EPIC v2.0 CNS tumor profiling demonstrates high reproducibility of tumor classification but reveals the need for harmonized copy number variation reporting

Brain Pathology, EarlyView.
Using the Infinium MethylationEPIC v2.0 array and Heidelberg Brain Tumor Classifier v12.8, 24 international laboratories achieved highly reproducible CNS tumor classification (97.9% correct; median β‐correlation r = 0.99), while copy number variation interpretation showed substantial interlaboratory variability, highlighting the need for harmonized CNV
Katrin Mauch‐Mücke, Christin Siewert, Lora Dimitrova, Sandra Pohl, Brendan Osberg, Annika K. Wefers, Julia Lorenz, Tanja Rothhammer‐Hampl, Till Acker, Alonso Barrantes‐Freer, Jean Boutonnat, Bérengère Dadone‐Montaudié, Claire Delbridge, Wolfgang Dietmaier, Sebastian Dintner, Hildegard Dohmen, Matthias Dottermusch, Daniel Erny, Katrin B. M. Frauenknecht, Tobias Goschzik, Patrick N. Harter, Daniela Hirsch, Yanghao Hou, Theo F. J. Kraus, Maggie Lee, Friederike Liesche‐Starnecker, Anne Mc Leer, Linea Melchior, Michael Mittelbronn, Wolf C. Müller, Shalima S. Nair, Julia E. Neumann, Pitt Niehusmann, Nicole Pfarr, Torsten Pietsch, Marco Prinz, Markus Rechsteiner, Regina Reimann, Laveniya Satgunaseelan, Veronica Skarpeteig, Anne J. Skjulsvik, Karl Sotlar, Isabelle Vanden Bempt, Erik Vassella, Katharina J. Weber, Gabriel Wasinger, Andreas Waha, Karen Zwaenepoel, Felix Sahm, Markus J. Riemenschneider, David Capper   +50 more
wiley   +1 more source

High-resolution array copy number analyses for detection of deletion, gain, amplification and copy-neutral LOH in primary neuroblastoma tumors: Four cases of homozygous deletions of the CDKN2A gene

BMC Genomics, 2008
Background Neuroblastoma is a very heterogeneous pediatric tumor of the sympathetic nervous system showing clinically significant patterns of genetic alterations.
Kogner Per, Abrahamsson Jonas, Sjöberg Rose-Marie, Enerbäck Charlotta, Olsson Linda, Erichsen Jennie, Carén Helena, Martinsson Tommy   +7 more
doaj   +1 more source